| 1 |
29445054 | Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures. | 2018 May 1 |
1 |
| 2 |
29731965 | TP53 and OSBPL10 alterations in diffuse large B-cell lymphoma: prognostic markers identified via exome analysis of cases with extreme prognosis. | 2018 Apr 13 |
2 |
| 3 |
28791403 | Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas. | 2017 Oct |
1 |
| 4 |
26238069 | TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer. | 2016 Jan 15 |
2 |
| 5 |
25430047 | Prognostic impact of the TP53 rs1625895 polymorphism in DLBCL patients. | 2015 Apr |
1 |
| 6 |
23759676 | Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapy. | 2013 Aug 1 |
1 |
| 7 |
24074787 | p53 in breast cancer subtypes and new insights into response to chemotherapy. | 2013 Aug |
1 |
| 8 |
24244905 | The Janus face of cyclophosphamide: A sterile inflammatory response that potentiates cancer immunotherapy. | 2013 Sep 1 |
1 |
| 9 |
21706156 | MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide. | 2012 Apr |
1 |
| 10 |
22139992 | Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study. | 2012 Sep 1 |
3 |
| 11 |
22955915 | Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. | 2012 Nov 8 |
1 |
| 12 |
23131146 | Chemosensitivity and p53; new tricks by an old dog. | 2012 Nov 6 |
1 |
| 13 |
21514041 | Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer. | 2011 Aug 28 |
1 |
| 14 |
21693655 | p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). | 2011 Aug 1 |
1 |
| 15 |
20228131 | Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. | 2010 |
3 |
| 16 |
20435884 | Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. | 2010 Aug 19 |
1 |
| 17 |
20638924 | Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy. | 2010 Oct |
1 |
| 18 |
20655369 | Activation of P53 in HepG2 cells as surrogate to detect mutagens and promutagens in vitro. | 2010 Oct 5 |
1 |
| 19 |
19372630 | Caspase mediated enhanced apoptotic action of cyclophosphamide- and resveratrol-treated MCF-7 cells. | 2009 Apr |
4 |
| 20 |
19731257 | The p53-mediated sensitivity of cancer cells to chemotherapeutic agents is conditioned by the status of the retinoblastoma protein. | 2009 Nov |
1 |
| 21 |
18325917 | p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. | 2008 Jul |
1 |
| 22 |
17388661 | Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. | 2007 Mar |
2 |
| 23 |
17876337 | Changes in allelic imbalances in locally advanced breast cancers after chemotherapy. | 2007 Oct 22 |
1 |
| 24 |
15182437 | Dependence of chemotherapy response on p53 mutation status in a panel of human cancer lines maintained in nude mice. | 2004 Jun |
2 |
| 25 |
11935300 | p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer. | 2002 Mar |
1 |
| 26 |
11332152 | Treatment based on a combination of the CYP2B1/cyclophosphamide system and p53 delivery enhances tumour regression in human pancreatic cancer. | 2001 Mar |
1 |
| 27 |
10472362 | p53 as a prognostic factor for stage III serous adenocarcinoma of the ovary. | 1999 May-Jun |
1 |
| 28 |
9610789 | p53 mutations in cyclophosphamide-associated bladder cancer. | 1998 May |
3 |
| 29 |
9703286 | Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. | 1998 Aug |
1 |
| 30 |
9951689 | Complete sequence of p53 gene in 20 patients with lung cancer: comparison with chemosensitivity and immunohistochemistry. | 1998 Dec |
1 |
| 31 |
9291435 | mdm 2 mRNA expression is associated with survival in ovarian cancer. | 1997 Aug 22 |
3 |
| 32 |
7563172 | Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. | 1995 Aug 16 |
1 |